Fujifilm Toyama Chemical Co. Ltd.
Division of Fujifilm Holdings Corp.
fftc.fujifilm.co.jp/en
Latest From Fujifilm Toyama Chemical Co. Ltd.
India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data
Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.
Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress
Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.
AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray
Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Company Information
- Industry
- In Vitro Diagnostics
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Cancer
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Toyama Chemical Co. Ltd.
- Fujifilm RI Pharma Co. Ltd.
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Fujifilm Holdings Corp.
- Senior Management
- Junji Okada, Pres.
- Contact Info
-
Fujifilm Toyama Chemical Co. Ltd.
Phone: (81) 3 5381 3889
14-1, Kyobashi 2-Chome
Chuo-ku
Tokyo ,
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice